These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24702722)

  • 1. Rituximab as first-line treatment for the management of adult patients with non-severe hemophilia A and inhibitors.
    Lim MY; Nielsen B; Lee K; Kasthuri RS; Key NS; Ma AD
    J Thromb Haemost; 2014 Jun; 12(6):897-901. PubMed ID: 24702722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment with rituximab in an elderly patient with acquired factor VIII inhibitor.
    Cretel E; Jean R; Chiche L; Durand JM
    Geriatr Gerontol Int; 2009 Jun; 9(2):197-9. PubMed ID: 19490140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia A.
    Kempton CL; Allen G; Hord J; Kruse-Jarres R; Pruthi RK; Walsh C; Young G; Soucie JM
    Am J Hematol; 2012 Sep; 87(9):933-6. PubMed ID: 22733686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitor development and management in three non-severe haemophilia A patients with T295A variant.
    Ivaskevicius V; Goldmann G; Horneff S; Marquardt N; Klein C; Albert T; Zeitler H; Oldenburg J
    Hamostaseologie; 2014; 34 Suppl 1():S9-12. PubMed ID: 25382774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired hemophilia in the patient suffering from rheumatoid arthritis: case report.
    Drobiecki A; Pasiarski M; Hus I; Sokołowska B; Wątek M
    Blood Coagul Fibrinolysis; 2013 Dec; 24(8):874-80. PubMed ID: 24042266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review.
    Hassan S; Cannavò A; Gouw SC; Rosendaal FR; van der Bom JG
    J Thromb Haemost; 2018 Jun; 16(6):1055-1068. PubMed ID: 29665204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors in nonsevere haemophilia A: outcome and eradication strategies.
    van Velzen AS; Eckhardt CL; Hart DP; Peters M; Rangarajan S; Mancuso ME; Smiers FJ; Khair K; Petrini P; Jiménez-Yuste V; Hay CR; van der Bom JG; Yee TT; Fijnvandraat K;
    Thromb Haemost; 2015 Jul; 114(1):46-55. PubMed ID: 25879247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab for treatment of inhibitors in haemophilia A. A Phase II study.
    Leissinger C; Josephson CD; Granger S; Konkle BA; Kruse-Jarres R; Ragni MV; Journeycake JM; Valentino L; Key NS; Gill JC; McCrae KR; Neufeld EJ; Manno C; Raffini L; Saxena K; Torres M; Marder V; Bennett CM; Assmann SF
    Thromb Haemost; 2014 Sep; 112(3):445-58. PubMed ID: 24919980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-A2 and anti-A1 domain antibodies are potential predictors of immune tolerance induction outcome in children with hemophilia A.
    Lapalud P; Rothschild C; Mathieu-Dupas E; Balicchi J; Gruel Y; Laune D; Molina F; Schved JF; Granier C; Lavigne-Lissalde G
    J Thromb Haemost; 2015 Apr; 13(4):540-7. PubMed ID: 25603934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twelve years of experience of acquired hemophilia A: trials and tribulations in South Australia.
    Tay L; Duncan E; Singhal D; Al-Qunfoidi R; Coghlan D; Jaksic W; Szabo F; McRae S; Lloyd J
    Semin Thromb Hemost; 2009 Nov; 35(8):769-77. PubMed ID: 20169513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
    Auerswald G; Spranger T; Brackmann HH
    Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune tolerance induction in patients with hemophilia A.
    Astermark J
    Thromb Res; 2011 Jan; 127 Suppl 1():S6-9. PubMed ID: 21056905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Haemate(®) P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: a multicentre observational study.
    Rothschild C; D'Oiron R; Borel-Derlon A; Gruel Y; Navarro R; Negrier C
    Haemophilia; 2013 Mar; 19(2):281-6. PubMed ID: 23038998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology of inhibitors and current treatment strategies.
    Kreuz W; Ettingshausen CE; Auerswald G; Saguer IM; Becker S; Funk M; Heller C; Klarmann D; Klingebiel T;
    Haematologica; 2003 Jun; 88(6):EREP04. PubMed ID: 12826530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2).
    Collins P; Baudo F; Knoebl P; Lévesque H; Nemes L; Pellegrini F; Marco P; Tengborn L; Huth-Kühne A;
    Blood; 2012 Jul; 120(1):47-55. PubMed ID: 22517903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitor development in non-severe haemophilia across Europe.
    Fischer K; Iorio A; Lassila R; Peyvandi F; Calizzani G; Gatt A; Lambert T; Windyga J; Gilman EA; Hollingsworth R; Makris M;
    Thromb Haemost; 2015 Oct; 114(4):670-5. PubMed ID: 26293381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study.
    Liesner RJ; Abraham A; Altisent C; Belletrutti MJ; Carcao M; Carvalho M; Chambost H; Chan AKC; Dubey L; Ducore J; Gattens M; Gresele P; Gruel Y; Guillet B; Jimenez-Yuste V; Kitanovski L; Klukowska A; Lohade S; Mancuso ME; Oldenburg J; Pavlova A; Pollio B; Sigaud M; Vdovin V; Vilchevska K; Wu JKM; Jansen M; Belyanskaya L; Walter O; Knaub S; Neufeld EJ
    Thromb Haemost; 2021 Nov; 121(11):1400-1408. PubMed ID: 33581698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitor eradication with rituximab in haemophilia: where do we stand?
    Franchini M; Mannucci PM
    Br J Haematol; 2014 Jun; 165(5):600-8. PubMed ID: 24628543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A low-dose rituximab regimen for first-line treatment of acquired haemophilia A.
    Hunt S; Robertson J; Conn J; Casey J; Royle J; Collins J; Hourigan M; Richmond J; Yang Wang T; Mills A; Mason J
    Eur J Haematol; 2022 Jan; 108(1):28-33. PubMed ID: 34528303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance.
    Miller CH; Platt SJ; Rice AS; Kelly F; Soucie JM;
    J Thromb Haemost; 2012 Jun; 10(6):1055-61. PubMed ID: 22435927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.